Literature DB >> 22775513

Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults.

Bilal Omer1, Nina S Kadan-Lottick, Kenneth B Roberts, Rong Wang, Carolyn Demsky, Gary M Kupfer, Dennis Cooper, Stuart Seropian, Xiaomei Ma.   

Abstract

To evaluate the impact of reduced radiation and combined modality therapy (CMT) in the treatment of Hodgkin lymphoma, we assessed the risk of second malignant neoplasms (SMNs) in patients who received extended-field radiotherapy only and patients who underwent CMT. Among 404 patients treated at Yale during 1970-2004, the risk of solid SMNs was elevated in the radiotherapy only group (n = 198, median follow-up = 21·1 years) compared to the general population, with a standardized incidence ratio (SIR) of 1·85 [95% confidence interval (CI): 1·17-2·78]. No increase was observed in the CMT group (n = 206, median follow-up = 14·3 years), although potential differences in SMN risk were indicated across the age spectrum in subgroup analysis. Patients who received mustard-containing regimens had increased risks for haematological SMNs (SIR = 8·74) and all SMNs (SIR = 1·85). When the analysis was stratified by age at diagnosis, children (0-20 years) had a significantly higher risk of SMNs (SIR = 5·24, 95% CI: 2·26-10·33), regardless of the treatment received. These findings suggest that recent treatment options utilizing lower dose radiation and less intense alkylator chemotherapy might be associated with lower incidences of SMNs among adults but not necessarily children.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22775513     DOI: 10.1111/j.1365-2141.2012.09211.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015.

Authors:  Lucie M Turcotte; Qi Liu; Yutaka Yasui; Michael A Arnold; Sue Hammond; Rebecca M Howell; Susan A Smith; Rita E Weathers; Tara O Henderson; Todd M Gibson; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Joseph P Neglia
Journal:  JAMA       Date:  2017-02-28       Impact factor: 56.272

2.  Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence.

Authors:  Wolfgang Dörffel; Marianne Riepenhausenl; Heike Lüders; Jürgen Brämswig; Günther Schellong
Journal:  Dtsch Arztebl Int       Date:  2015-05-01       Impact factor: 5.594

Review 3.  A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies.

Authors:  Marlise R Luskin; Rahul Banerjee; Sarah Del Percio; Alison W Loren
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 4.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

5.  Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

Review 6.  Controversies in the role of radiotherapy in the treatment of pediatric Hodgkin lymphoma.

Authors:  Meret Henry; Süreyya Savaşan
Journal:  Indian J Pediatr       Date:  2013-08-24       Impact factor: 1.967

Review 7.  Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.

Authors:  Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-10-11

8.  Radiation-induced malignancies after intensity-modulated versus conventional mediastinal radiotherapy in a small animal model.

Authors:  Kaga Gomarteli; Jens Fleckenstein; Stefanie Kirschner; Vladimir Bobu; Marc A Brockmann; Thomas Henzler; Mathias Meyer; Philipp Riffel; Stefan O Schönberg; Marlon R Veldwijk; Bettina Kränzlin; Christian Hoerner; Gerhard Glatting; Frederik Wenz; Carsten Herskind; Frank A Giordano
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.